e-Drug3D

1829

M MIDOSTAURIN

INN
MIDOSTAURIN

cas 740816-86-8

CLASS

ANTINEOPLASTIC
TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) OR AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM)
MULTIKINASE TYROSINE KINASE INHIBITOR (FLT3, FLT3 MUTANT KINASES (ITD AND TKD), KIT (WILD TYPE AND D816V MUTANT), PDGFR ALPHA/BETA, VEGFR2, AS WELL AS MEMBERS OF THE SERINE/THREONINE KINASE PKC (PROTEIN KINASE C) FAMILY)

ROUTE (list)

ATC code

L01EX10

PK parameters

PPB 99.8 PERCENT
t1/2 32 HOUR

Target

TARGET FLT3 KINASE
FLT3 MUTANT KINASES
KIT
PDGFR
VEGFR2
SERINE/THREONINE KINASE PKC

DrugCentral

Receptor-type tyrosine-protein kinase FLT3 UNIPROT P36888 FLT3

Download SDF file

Benzamide, N-[(9S,10R,11R,13R)-2,3,10,11,12,13-hexahydro-10-hydroxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl]-N-methyl-

Formula:
C34H28N4O4

Calculated chemical properties:

MW 556.60
NB_atoms 42
XLogP 5.25
PSA 65.825
NB_HD 2
NB_HA 8
fsp3 0.24
Lipinski(0=no;1=yes) 0

FDA
-